Kainos Medicine Inc
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company's product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson's disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to tre… Read more
Kainos Medicine Inc - Asset Resilience Ratio
Kainos Medicine Inc (284620) has an Asset Resilience Ratio of 48.13% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Kainos Medicine Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Kainos Medicine Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩6.43 Billion | 48.13% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩6.43 Billion | 48.13% |
Asset Resilience Insights
- Very High Liquidity: Kainos Medicine Inc maintains exceptional liquid asset reserves at 48.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Kainos Medicine Inc Industry Peers by Asset Resilience Ratio
Compare Kainos Medicine Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Kainos Medicine Inc (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Kainos Medicine Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 35.69% | ₩3.83 Billion | ₩10.74 Billion | -42.16pp |
| 2023-12-31 | 77.85% | ₩16.34 Billion | ₩20.99 Billion | +1.02pp |
| 2022-12-31 | 76.83% | ₩29.95 Billion | ₩38.98 Billion | -4.75pp |
| 2021-12-31 | 81.59% | ₩34.23 Billion | ₩41.96 Billion | -4.13pp |
| 2020-12-31 | 85.72% | ₩29.81 Billion | ₩34.78 Billion | -13.35pp |
| 2019-12-31 | 99.07% | ₩10.60 Billion | ₩10.70 Billion | -0.06pp |
| 2018-12-31 | 99.12% | ₩10.51 Billion | ₩10.60 Billion | -0.87pp |
| 2017-12-31 | 100.00% | ₩1.69 Billion | ₩1.69 Billion | -- |